As outlined in our earlier blog the Joint Committee on Vaccination & Immunisation have published their paper recommending that the Bexsero Meningitis B vaccine not be implemented in the UK, due to concerns over cost. Charities such as the Meningitis Research Foundation have been invited to comment on the draft statement prepared by the Committee by 3 September 2013, before final recommendations are made to the Government.
The Meningitis Research Foundation’s ambassadors recently submitted a detailed letter to Prime Minister David Cameron, urging him to give proper consideration to the issue and challenging the basis of the cost/benefit argument. They have suggested that the cost of lifelong care and support for survivors of the disease (who often suffer amputation, hearing loss or brain damage) far outweighs the cost of a national vaccination programme for infants.
In the past 24 hours, Australia is the latest country to approve licensing for the Meningitis B vaccine. Many countries in Europe have also approved its use. Will the UK follow suit?